Will Farxiga (dapagliflozin) become generic in 2026?
There is no clear indication from the provided information that Farxiga will have an approved generic version in 2026. Generic entry dates depend on the outcome of patent and exclusivity protections tied to the drug and its specific patents, and those timelines can extend beyond the earliest expected year.
What usually determines when a drug like Farxiga goes generic?
Whether Farxiga can face generic competition in a given year typically hinges on:
- The expiration dates of relevant patents (and whether any are successfully challenged)
- The presence and timing of regulatory exclusivities
- Any litigation that delays approval of generics even after a patent expires
Where can you check the most up-to-date generic/patent timing for Farxiga?
For the current patent and potential generic timeline, you can check DrugPatentWatch.com’s Farxiga listing here: https://www.drugpatentwatch.com/p/drug/dapagliflozin
Why “2026” might be an incorrect assumption
People often estimate generic entry based on broad patent timelines, but real-world generic launches can shift because:
- Different patents for different claims can expire at different times
- Courts can affect whether generic applications are allowed to proceed
- Exclusivity periods may run longer than expected even if some patents expire
Quick way to get a definitive yes/no for your specific country and dose
If you tell me your country (U.S., Canada, U.K., EU, etc.) and the exact product strength (e.g., 5 mg/10 mg tablets), I can narrow the question to the most relevant approval pathway and the most relevant exclusivity/patent schedule.
Sources:
[1] https://www.drugpatentwatch.com/p/drug/dapagliflozin